EATONTOWN, N.J., Aug. 27 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Amex: RPC) today announced the election of Joseph E. Smith to its
Board of Directors. Roberts said that with today's announcement, its Board
will consist of nine members with Mr. Smith joining as the fifth outside
director.
From 1989 until retiring in 1997, Joseph E. Smith served in various
positions with the Warner-Lambert Company including President of Parke-Davis
Pharmaceuticals; President of Shaving Products Division; and Member of the
Office of the Chairman. Additionally, with prior positions at Johnson &
Johnson and as President of Rorer Pharmaceutical Corporation, Mr. Smith
possesses an extensive background and a wealth of experience in pharmaceutical
and consumer product businesses, both domestic and internationally.
In addition to serving on the board of other pharmaceutical companies,
Mr. Smith has served as a board member of the Philadelphia College of Pharmacy
and Science; Alliance for Aging Research; Japan-American Pharmaceutical
Committee; National Association of Chain Drug Stores; and the Non-Prescription
Drug Manufacturers Association. He received an MBA degree from the Wharton
School of the University of Pennsylvania.
Commenting on today's announcement, Dr. Robert A. Vukovich, the Executive
Chairman of Roberts' Board of Directors, said, "We are fortunate to have an
individual with the breadth of experience of Joseph Smith join our Board. His
background, proven talents, and industry knowledge complement the strengths of
our distinguished board members and all of us look forward to his input and
guidance."
John T. Spitznagel, President and CEO of Roberts noted, "We are delighted
to have such an eminently qualified professional join the Roberts' Board.
Joseph Smith has an exceptional pharmaceutical career and his election to our
Board reflects Roberts continued focus and commitment to growth,
profitability, and enhanced shareholder value."
Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada and the United Kingdom, is a fully integrated
pharmaceutical company. Roberts focuses on licensing, acquiring, developing
and commercializing innovative and value-added pharmaceuticals for both niche
and large pharmaceutical markets, with the Company having strategic interests
in the therapeutic categories of gastroenterology, cardiology,
oncology/hematology, and urology.
This and past press releases of Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On Call fax service at
800-758-5804, extension 760975 and through the internet at
http://www.prnewswire.com as well as the Company's home page at
http://www.robertspharm.com.
This release may contain forward-looking statements which are based on
assumptions and external factors, including assumptions relating to, but not
limited to regulatory action, product pricing, competitive market conditions,
financial data, new product development and other risks or uncertainties
detailed from time to time in Roberts filings with the Securities and Exchange
Commission. These forward-looking statements represent the Company's judgment
as of the date of this release and any changes in the assumptions or external
factors could produce significantly different results.
SOURCE Roberts Pharmaceutical Corporation
 back to top
Related links:
http://www.robertspharm.com
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 760975
CONTACT:
Stuart Z. Levine, Ph.D., Director of Investor
Relations of Roberts Pharmaceutical Corporation, 732-676-1200,
ext. 3064
|
